|
SRP19 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.21659999996471E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.86880000002865E-06 |
| Normal-vs-Stage2 |
1.346650E-01 |
| Normal-vs-Stage3 |
2.77970000017724E-07 |
| Normal-vs-Stage4 |
4.35939999654522E-08 |
| Stage1-vs-Stage2 |
1.525370E-01 |
| Stage1-vs-Stage3 |
1.839020E-01 |
| Stage1-vs-Stage4 |
1.794420E-02 |
| Stage2-vs-Stage3 |
4.350300E-02 |
| Stage2-vs-Stage4 |
6.761800E-03 |
| Stage3-vs-Stage4 |
1.979580E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.83130000053211E-07 |
| Normal-vs-AfricanAmerican |
1.009580E-04 |
| Normal-vs-Asian |
9.53069999587441E-08 |
| Caucasian-vs-AfricanAmerican |
4.195600E-01 |
| Caucasian-vs-Asian |
2.506400E-01 |
| AfricanAmerican-vs-Asian |
8.609400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.27480000000624E-07 |
| Normal-vs-Female |
2.07249999999437E-05 |
| Male-vs-Female |
1.201820E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.854899999853E-07 |
| Normal-vs-Age(41-60Yrs) |
1.95199999997175E-06 |
| Normal-vs-Age(61-80Yrs) |
3.155100E-04 |
| Normal-vs-Age(81-100Yrs) |
3.538000E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.629600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.782800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.999980E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.892800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.165800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.751200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.419700E-02 |
| Classical-VS-Follicular |
3.57870000000649E-05 |
| Classical-VS-Other |
2.665400E-01 |
| Classical-VS-Normal |
1.86530002554974E-09 |
| Tall-VS-Follicular |
1.0107000000259E-06 |
| Tall-VS-Other |
6.158200E-01 |
| Tall-VS-Normal |
4.64070004646544E-09 |
| Follicular-VS-Other |
4.149700E-02 |
| Follicular-VS-Normal |
4.326800E-01 |
| Other-VS-Normal |
1.019330E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.024340E-04 |
| Normal-vs-N1 |
1.2339999999611E-07 |
| N0-vs-N1 |
2.440000E-02 |
|
|
